Byhealth Valuation
Is 300146 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300146 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300146 (CN¥12.4) is trading below our estimate of fair value (CN¥30.9)
Significantly Below Fair Value: 300146 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300146?
Key metric: As 300146 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 300146's PE Ratio? | |
|---|---|
| PE Ratio | 29.3x |
| Earnings | CN¥713.82m |
| Market Cap | CN¥20.90b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | 21.5x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 300146's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.1x | ||
603868 Shanghai Flyco Electrical Appliance | 26.7x | 16.0% | CN¥17.5b |
300957 Yunnan Botanee Bio-Technology GroupLTD | 34x | 33.3% | CN¥20.1b |
603983 Guangdong Marubi Biotechnology | 34.2x | 24.0% | CN¥11.1b |
600315 Shanghai Jahwa United | 41.5x | 27.5% | CN¥11.2b |
300146 Byhealth | 29.3x | 34.8% | CN¥20.9b |
Price-To-Earnings vs Peers: 300146 is good value based on its Price-To-Earnings Ratio (29.3x) compared to the peer average (34.1x).
Price to Earnings Ratio vs Industry
How does 300146's PE Ratio compare vs other companies in the CN Personal Products Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 300146 is good value based on its Price-To-Earnings Ratio (29.3x) compared to the CN Personal Products industry average (35.1x).
Price to Earnings Ratio vs Fair Ratio
What is 300146's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.3x |
| Fair PE Ratio | 36.6x |
Price-To-Earnings vs Fair Ratio: 300146 is good value based on its Price-To-Earnings Ratio (29.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥12.40 | CN¥14.97 +20.7% | 10.9% | CN¥16.75 | CN¥12.00 | n/a | 6 |
| Nov ’25 | CN¥12.62 | CN¥14.61 +15.8% | 10.7% | CN¥16.70 | CN¥12.00 | n/a | 5 |
| Oct ’25 | CN¥14.90 | CN¥16.68 +11.9% | 20.8% | CN¥24.00 | CN¥13.00 | n/a | 6 |
| Sep ’25 | CN¥11.29 | CN¥16.67 +47.7% | 22.8% | CN¥24.00 | CN¥13.00 | n/a | 5 |
| Aug ’25 | CN¥13.24 | CN¥22.19 +67.6% | 21.2% | CN¥31.00 | CN¥17.20 | n/a | 5 |
| Jul ’25 | CN¥13.79 | CN¥22.19 +60.9% | 21.2% | CN¥31.00 | CN¥17.20 | n/a | 5 |
| Jun ’25 | CN¥15.12 | CN¥22.19 +46.8% | 21.2% | CN¥31.00 | CN¥17.20 | n/a | 5 |
| May ’25 | CN¥15.84 | CN¥22.19 +40.1% | 21.2% | CN¥31.00 | CN¥17.20 | n/a | 5 |
| Apr ’25 | CN¥17.17 | CN¥22.99 +33.9% | 18.8% | CN¥31.00 | CN¥18.20 | n/a | 5 |
| Mar ’25 | CN¥16.78 | CN¥26.39 +57.3% | 12.0% | CN¥31.00 | CN¥23.00 | n/a | 4 |
| Feb ’25 | CN¥15.17 | CN¥26.39 +74.0% | 12.0% | CN¥31.00 | CN¥23.00 | n/a | 4 |
| Jan ’25 | CN¥17.03 | CN¥25.67 +50.7% | 12.3% | CN¥31.00 | CN¥22.80 | n/a | 5 |
| Dec ’24 | CN¥18.23 | CN¥25.67 +40.8% | 12.3% | CN¥31.00 | CN¥22.80 | n/a | 5 |
| Nov ’24 | CN¥18.32 | CN¥26.37 +44.0% | 10.7% | CN¥31.00 | CN¥23.00 | CN¥12.62 | 5 |
| Oct ’24 | CN¥18.99 | CN¥28.57 +50.5% | 5.9% | CN¥31.00 | CN¥26.30 | CN¥14.90 | 5 |
| Sep ’24 | CN¥19.38 | CN¥28.57 +47.4% | 5.9% | CN¥31.00 | CN¥26.30 | CN¥11.29 | 5 |
| Aug ’24 | CN¥21.19 | CN¥27.97 +32.0% | 4.8% | CN¥30.00 | CN¥26.30 | CN¥13.24 | 4 |
| Jul ’24 | CN¥23.98 | CN¥27.97 +16.6% | 4.8% | CN¥30.00 | CN¥26.30 | CN¥13.79 | 4 |
| Jun ’24 | CN¥22.44 | CN¥27.97 +24.7% | 4.3% | CN¥30.00 | CN¥26.30 | CN¥15.12 | 5 |
| May ’24 | CN¥23.88 | CN¥27.97 +17.1% | 4.3% | CN¥30.00 | CN¥26.30 | CN¥15.84 | 5 |
| Apr ’24 | CN¥21.35 | CN¥27.73 +29.9% | 5.6% | CN¥30.00 | CN¥25.10 | CN¥17.17 | 5 |
| Mar ’24 | CN¥22.97 | CN¥27.59 +20.1% | 3.7% | CN¥28.50 | CN¥25.60 | CN¥16.78 | 5 |
| Feb ’24 | CN¥23.01 | CN¥27.59 +19.9% | 3.7% | CN¥28.50 | CN¥25.60 | CN¥15.17 | 5 |
| Jan ’24 | CN¥22.82 | CN¥26.55 +16.3% | 15.8% | CN¥33.90 | CN¥20.88 | CN¥17.03 | 6 |
| Dec ’23 | CN¥20.37 | CN¥25.13 +23.4% | 18.7% | CN¥33.90 | CN¥20.00 | CN¥18.23 | 6 |
| Nov ’23 | CN¥18.13 | CN¥25.36 +39.9% | 20.2% | CN¥33.90 | CN¥20.00 | CN¥18.32 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Shenzhen Breo Technology
CN¥2.5b
Researches and develops portable massage products for headache swelling, eye fatigue, and shoulder and neck pain.
688793
CN¥29.69
7D
-1.7%
1Y
-24.3%
SYoung Group
CN¥4.8b
Engages in the research and development, production, and sale of cosmetic products in China.
300740
CN¥12.30
7D
-4.1%
1Y
-27.0%
SYoung Group
CN¥4.8b
Engages in the research and development, production, and sale of cosmetic products in China.
300740
CN¥12.30
7D
-4.1%
1Y
-27.0%